PolyActiva and RareSight Form Strategic Collaboration to Develop Breakthrough Treatments for Rare Pediatric Retinal Diseases
PolyActiva, a clinical-stage biopharmaceutical company pioneering a novel drug delivery technology to improve outcomes for patients with ocular conditions, and RareSight, Inc., an ophthalmology-focused life sciences company committed to advancing therapies for inherited retinal diseases (IRDs), today announced a strategic collaboration to develop first-in-class therapies for rare pediatric retinal diseases that currently have no approved drug treatments.
PolyActiva to Present Advancements in Next-Generation Ocular Micro-Implant Technology at Eyecelerator® @ AAO 2025
PolyActiva, a clinical-stage biopharmaceutical company pioneering a novel drug delivery technology to improve outcomes for patients with ocular conditions, today announced that Michael Brubaker, Ph.D., Chief Scientific Officer, will present a corporate overview at Eyecelerator® @ the American Academy of Ophthalmology (AAO) 2025 Annual Meeting on Thursday, October 16, 2025, in Orlando, Florida.
PolyActiva Announces First Patient Enrolled in US Phase 2b Clinical Trial of its Ocular Micro Implant for Glaucoma and Ocular Hypertension
PolyActiva, a clinical-stage biopharmaceutical company pioneering a novel drug delivery technology to improve outcomes for patients with ocular conditions, today announced that the first U.S. patient has been enrolled in the company’s Phase 2b clinical trial evaluating PA5108, an investigational, new chemical entity (NCE), intracameral ocular micro implant, for the reduction in intraocular pressure (IOP) for patients with primary open-angle glaucoma (POAG) and ocular hypertension (OHT).
PolyActiva Expands Executive Team to Drive Transformational Growth and Advance Late-Stage Clinical Development in the U.S.
PolyActiva, a clinical-stage biopharmaceutical company pioneering a novel drug delivery technology to improve outcomes for patients with ocular conditions, today announced the appointments of Wes Brazell as Chief Financial Officer (CFO) and Michael Brubaker, PhD, as Chief Scientific Officer (CSO).
PolyActiva Appoints Jerry St. Peter as CEO and Secures $25M Series C Financing to Accelerate US Expansion and Clinical Advancement of PREZIA™ Technology Platform
PolyActiva, a clinical-stage biopharmaceutical company pioneering a novel drug delivery technology to improve outcomes for patients with ocular conditions, today announced two major milestones in its next phase of growth: the appointment of seasoned biopharmaceutical executive, Jerry St. Peter as CEO and board director, and the successful close of a $25M Series C funding round led by an Australian Sovereign Wealth Fund with continued strong support from Brandon Capital.
